press-releases Archives - Page 4 of 8 - Bladder cancer | Oncolytic immunotherapy | cretostimogene grenadenorepvec | CG Oncology - CG Oncology

CG Oncology Announces…

Home PRESS RELEASE CG Oncology Announces Pricing of Upsized Initial Public Offering 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== --> Listen to this article now 0:00...

CG Oncology Receives…

Home PRESS RELEASE CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to...

Cretostimogene Grena…

Home PRESS RELEASE Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen...

CG Oncology Announces…

Home PRESS RELEASE CG Oncology Announces Presentation of the First Phase 3 Monotherapy Data for Cretostimogene Grenadenorepvec in BCG-Unresponsive NMIBC Patients at SUO 2023 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱...

CG Oncology Announces…

Home PRESS RELEASE CG Oncology Announces Key Executive Appointments in Commercialization, Medical and Manufacturing Operations 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...

CG Oncology Announces…

Home PRESS RELEASE CG Oncology Announces $105 Million Oversubscribed Crossover Financing to Support Continued Advancement of Clinical-Stage Bladder Cancer Pipeline 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE...